Pollen extract for chronic prostatitis-chronic pelvic pain syndrome

Urologic Clinics of North America

Volumn 38, Issue 3, 2011, Pages 285-292

  Wagenlehner, Florian M E ^a   Bschleipfer, Thomas ^a   Pilatz, Adrian ^a   Weidner, Wolfgang ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Chronic pelvic pain syndrome; Chronic prostatitis; Chronic prostatitis symptom index; Clinical efficacy; Pollen extract

Indexed keywords

CERNITIN; CERNITIN T60; DICLOFENAC; INDOMETACIN; PLACEBO; POLLEN EXTRACT; POLTIT; PROSTAT; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CHRONIC PROSTATITIS; DISEASE MODEL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; FOLLOW UP; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PELVIS PAIN SYNDROME; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOOTH MUSCLE; UNSPECIFIED SIDE EFFECT;

HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; POLLEN; PROSTATITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79960630043     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.04.004     Document Type: Review

References (45)

1. Schaeffer A.J. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 2006, 355(16):1690-1698.
2. Magri V., Wagenlehner F., Perletti G., et al. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. J Urol 2010, 184(6):2339-2345.
3. Schaeffer AJ, Anderson, RU, Krieger, JN, et al. The assessment and management of male pelvic pain syndrome, including prostatitis. Committee 15. In: McConnell J, Abrams P, Denis L, et al, editors. Male Lower Urinary tract dysfucntion. Evaluation and Management. 9th International Consultation on New Developments in Prostate Cancer and Prostatitic Diseases, Paris (France), June 24-27, 2005; Health Publications: 2006. p. 341-75.
4. Krieger J.N., Nyberg L., Nickel J.C. NIH consensus definition and classification of prostatitis. JAMA 1999, 282(3):236-237.
5. Schaeffer A.J. Prostatitis: US perspective. Int J Antimicrob Agents 1999, 11(3-4):205-211. [discussion: 213-6].
6. Shoskes D.A., Nickel J.C., Dolinga R., et al. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 2009, 73(3):538-542. [discussion: 542-3].
7. Gonzalez R.R., Te A.E. Chronic prostatitis and sensory urgency: whose pain is it?. Curr Urol Rep 2004, 5(6):437-441.
8. Karlovsky M.E., Pontari M.A. Theories of prostatitis etiology. Curr Urol Rep 2002, 3(4):307-312.
9. Nickel J.C., Krieger J.N., McNaughton-Collins M., et al. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med 2008, 359(25):2663-2673.
10. Anothaisintawee T., Attia J., Nickel J.C., et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 2011, 305(1):78-86.
11. Rugendorff E.W., Weidner W., Ebeling L., et al. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol 1993, 71(4):433-438.
12. Shoskes D.A. Phytotherapy in chronic prostatitis. Urology 2002, 60(Suppl 6):35-37. [discussion: 37].
13. Wagenlehner F.M., Schneider H., Ludwig M., et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol 2009, 56(3):544-551.
14. Buck A.C., Cox R., Rees R.W., et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study. Br J Urol 1990, 66(4):398-404.
15. Buck A.C., Rees R.W., Ebeling L. Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol 1989, 64(5):496-499.
16. Pharmacological Studies of CERNILTON, Cernitin GBX and Cernitin T60 1968, Tobishi Pharmaceutical Co., LTD, Tokyo.
17. Nakase K., Takenag K., Hamanaka T., et al. Nippon Yakurigaku Zasshi 1988, 91:385-392. [in Japanese].
18. Onodera S., Yoshinaga M., Takenaga K., et al. Effects of Cernitin extract (CN-009) on the isolated bladder smooth muscles and the intravesical pressure. Nippon Yakurigaku Zasshi 1991, 97:267-276.
19. Nagashima A., Ishii M., Yoshinaga M., et al. Effect of Cernitin extract (Cernilton) on the function of urinary bladder in conscious rats. Japan Pharmacol Ther 1998, 26(11).
20. Loschen G., Ebeling L. Arzneimittelforschung 1991, 41(2):162-167. [in German].
21. Asakawa K., Nandachi N., Satoh S., et al. Hinyokika Kiyo 2001, 47(7):459-465.
22. Kawakami J., Siemens D.R., Nickel J.C. Prostatitis and prostate cancer: implications for prostate cancer screening. Urology 2004, 64(6):1075-1080.
23. Tunn S., Krieg M. Alterations in the intraprostatic hormonal metabolism by the pollen extract Cernilton. Benign prostate diseases 1992, 109-114. Georg Thieme Verlag, Stuttgart (Germany); New York. W. Vahlensieck, G. Rutischauser (Eds.).
24. Talpur N., Echard B., Bagchi D., et al. Comparison of Saw Palmetto (extract and whole berry) and Cernitin on prostate growth in rats. Mol Cell Biochem 2003, 250(1-2):21-26.
25. Habib F.K. Regulation of prostate growth in culture with the Pollen Extract Cernitin T60 and the impact of the drug on the EGF tissue profile. Benign prostate diseases 1992, 115-122. Georg Thieme Verlag, Stuttgart (Germany); New York. W. Vahlensieck, G. Rutishauser (Eds.).
26. Kamijo T., Sato S., Kitamura T. Effect of cernitin pollen-extract on experimental nonbacterial prostatitis in rats. Prostate 2001, 49(2):122-131.
27. Ebeling L. Therapeutic results of defined Pollen-extract in patients with chronic prostatitis or BPH accompanied by chronic prostatitis. Therapy of prostatitis 1986, 154-160. Zuckerschwerd, München (Germany); Bern, Wien, San Francisco. W. Weidner, H. Brunner, W. Krause (Eds.).
28. Elist J. Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study. Urology 2006, 67(1):60-63.
29. Monden K., Tsugawa M., Ninomiya Y., et al. Nippon Hinyokika Gakkai Zasshi 2002, 93(4):539-547. [in Japanese].
30. Li N.C., Na Y.Q., Guo H.Q. Clinical study with Prostat (Poltit) for treatment for chronic nonbacterial prostatitis. Chin J Urol 2003, 24:635-637.
31. Jodai A., Maruta N., Shimomae E., et al. Hinyokika Kiyo 1988, 34(3):561-568. [in Japanese].
32. Suzuki T., Kurokawa K., Mashimo T., et al. Hinyokika Kiyo 1992, 38(4):489-494. [in Japanese].
33. Hochreiter W., Ludwig M., Weidner W., et al. Urologe A 2001, 40(1):16-17. [in German].
34. Wagenlehner F.M.E., Schneider H., Ludwig M., et al. Long term efficacy of Cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. Eur Urol Suppl 2009, 8(4):260. [abstract 559].
35. Bjerklund Johansen T.E., Gruneberg R.N., Guibert J., et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 1998, 34(6):457-466.
36. Tugcu V., Tasci A.I., Fazlioglu A., et al. A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol 2007, 51(4):1113-1117. [discussion: 1118].
37. Naber K.G., Bergman B., Bishop M.C., et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001, 40(5):576-588.
38. Capodice J.L., Bemis D.L., Buttyan R., et al. Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain syndrome. Evid Based Complement Alternat Med 2005, 2(4):495-501.
39. Lee C.B., Ha U.S., Lee S.J., et al. Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World J Urol 2006, 24(1):55-60.
40. Kaplan S.A., Volpe M.A., Te A.E. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol 2004, 171(1):284-288.
41. Shoskes D.A., Zeitlin S.I., Shahed A., et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999, 54(6):960-963.
42. Shoskes D.A. Phytotherapy and other alternative forms of care for the patient with prostatitis. Curr Urol Rep 2002, 3(4):330-334.
43. Nickel J.C., Pontari M., Moon T., et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol 2003, 169(4):1401-1405.
44. Nickel J.C. Role of alpha1-blockers in chronic prostatitis syndromes. BJU Int 2008, 101(Suppl 3):11-16.
45. Shoskes D.A., Nickel J.C., Kattan M.W. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology 2010, 75(6):1249-1253.